Baicheng Pharmaceutical: Legal Opinion of Beijing Hairun Tianrui Law Firm on the granting of price adjustments to Hangzhou Baicheng Pharmaceutical Technology Co., Ltd., the fulfillment of ownership conditions during the second vesting period, and the abolition of some restricted shares
Baicheng Pharmaceutical: Announcement on the 2022 Restricted Stock Incentive Plan for Cancelled Companies Partially Granted Restricted Shares Not Owned
Baicheng Pharmaceutical: Announcement on the achievement of the vesting conditions for the first time and the second reserved portion of the 2022 Restricted Stock Incentive Plan
Baicheng Pharmaceutical: Announcement of Resolutions of the 19th Meeting of the Third Board of Supervisors
Baicheng Pharmaceutical: Announcement of Resolutions of the 23rd Meeting of the Third Board of Directors
Baicheng Pharmaceutical: Independent Financial Advisory Report of Shanghai Xingong Yihe Enterprise Management Consulting Co., Ltd. on matters relating to the ownership of the first 2022 restricted stock incentive plan of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd., and part of the second vesting period of the reserved grant
Baicheng Pharmaceutical: Announcement on Adjusting the Price Granted by the Company\'s 2022 Restricted Stock Incentive Plan
Baicheng Pharmaceutical: Supervisory Board\'s Review of the Vesting List for the First Time and Second Reserved Part of the 2022 Restricted Stock Incentive Plan
Hangzhou Bio-Sincerity Pharma-Tech: Board of directors resolution announcement.
Hangzhou Bio-Sincerity Pharma-Tech: Special report on the use and placement of funds raised during the first half of 2024.
Hangzhou Bio-Sincerity Pharma-Tech: Summary of Half-Year Report in 2024.
Hangzhou Bio-Sincerity Pharma-Tech: Summary table of non-operating fund use and other related fund transactions for the first half of 2024.
Hangzhou Bio-Sincerity Pharma-Tech: Sinolink Securities Co., Ltd.'s Continuous Supervision and Follow-up Report on Hangzhou Baicheng Pharmaceutical Technology Co., Ltd.'s 2024 Half-Yearly
Hangzhou Bio-Sincerity Pharma-Tech: Announcement of the Supervisory Board's resolution.
Hangzhou Bio-Sincerity Pharma-Tech: Half-year report for the year 2024.
Hangzhou Bio-Sincerity Pharma-Tech: Announcement Regarding the Technology Transfer of Type 2 Improved New Drug 2022HY052
Hangzhou Bio-Sincerity Pharma-Tech: 2023 Annual Equity Distribution Implementation Notice
Hangzhou Bio-Sincerity Pharma-Tech: Announcement on BIOS2220 receiving a clinical trial approval notice
Hangzhou Bio-Sincerity Pharma-Tech: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Hangzhou Bio-Sincerity Pharma-Tech: Legal Opinion of Beijing Hairun Tianrui Law Firm on the 2023 Annual General Meeting of Shareholders of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd.
No Data
No Data